Clinical Pipeline
- Clinical Pipeline
- Preclinical Pipeline
- Diagnostic Program
AC Immune develops innovative therapeutics with “best in class” potential against Alzheimer's Disease along three axes: vaccines, antibodies and small molecules. In every axis one product is currently in clinical development. These product programs are based on the Abeta hypothesis, which assigns a central role to abnormal processing of amyloid precursor protein (APP), yielding a fragment called Abeta. Abeta production and aggregation are seen as one key event in nerve cell disruption and destruction.
ACI-24 (Active Alzheimer's Disease Immunotherapy)
ACI-24 has been developed from the SupraAntigen™ Platform and is designed to act as an active vaccine stimulating the patient's immune system to produce beta-sheet conformation-specific antibodies that prevent plaque deposition or enhance clearance of plaques. During preclinical development, the ACI-24 has shown high efficacy in vivo by memory restoration and plaque reduction. The vaccine is also characterized by a very high specificity due to generating a conformation-specific antibody response. The favorable safety profile of ACI-24 is underlined through the absence of local inflammation in relevant models as well as its T-cell independent mechanism shown in preclinical development. This product entered a Phase I clinical trial in 2009.
Anti-Abeta (Passive Alzheimer's Disease Immunotherapy)
The anti-Abeta antibody is being developed by Genentech, Inc. - under an exclusive licensing agreement with AC Immune - for an Alzheimer´s Disease immunotherapy against Abeta. This monoclonal antibody has as well been developed from the SupraAntigen™ Platform. The pre-clinical assessment of the antibody has shown high specificity and efficacy as well as a favorable safety profile. Genentech was granted Investigational New Drug clearance by the FDA and fast track status was designated. The Phase I clinical study commenced in 2008 and is currently ongoing.
ACI-91 (Small Molecule)
ACI-91 is an oral compound with the potential to prevent and/or slow down Alzheimer´s Disease. The disease-modifying properties are linked to BACE1 modulation demonstrated in vitro and in vivo. The high efficacy has been proven through plaque reduction and prevention of memory loss. The compound has an outstanding safety profile due to its long history of safe use in people. ACI-91 entered Phase II clinical studies in 2008 which are currently ongoing.
